References
- 1. Eng C. Familial Papillary Thyroid Cancer – Many Syndromes, Too Many Genes? J Clin Endocrinol Metab [Internet]. 2000;85(5):1755–7. Available from: http://press.endocrine.org/doi/abs/10.1210/jcem.85.5.6632
- 2. Jindrichova S, Vlcek P, Bendlova B. [Genetic causes of the thyroid carcinomas]. Cas Lek Ces [Internet]. 2004;143(10):664–8. Available from: http://www.ncbi.nlm.nih.gov/pubmed/15584614
- 3. Moses W, Weng J, Kebebew E. Prevalence, clinicopathologic features, and somatic genetic mutation profile in familial versus sporadic nonmedullary thyroid cancer. Thyroid [Internet]. 2011;21(4):367–71. Available from: http://www.ncbi.nlm.nih.gov/pubmed/21190444
- 4. Rios A, Rodriguez JM, Navas D et al. Family Screening in Familial Papillary Carcinoma: The Early Detection of Thyroid Disease. Ann Surg Oncol. 2016/03/30. 2016;23(8):2564–70.
- 5. Dupuy A, Simon RM. Critical Review of Published Microarray Studies for Cancer Outcome and Guidelines on Statistical Analysis and Reporting. JNCI J Natl Cancer Inst [Internet]. 2007;99(2):147–57. Available from: http://dx.doi.org/10.1093/jnci/djk018
- 6. Lin R-Y. Thyroid cancer stem cells. Nat Rev Endocrinol [Internet]. 2011;7:609. Available from: http://dx.doi.org/10.1038/nrendo.2011.127.
- 7. Kondo T, Ezzat S, Asa SL. Pathogenetic mechanisms in thyroid follicular-cell neoplasia. Nat Rev Cancer. 2006;6(4):292.
- 8. Parameswaran R, Brooks S, Sadler GP. Molecular pathogenesis of follicular cell derived thyroid cancers. Int J Surg. 2010;8(3):186–93.
- 9. Takano T. Fetal cell carcinogenesis of the thyroid: theory and practice. In: Seminars in cancer biology. Elsevier; 2007. p. 233–40.
- 10. Friedman S, Lu M, Schultz A et al. CD133+ anaplastic thyroid cancer cells initiate tumors in immunodeficient mice and are regulated by thyrotropin. PLoS One. 2009;4(4):e5395.
- 11. Zito G, Richiusa P, Bommarito A et al. In vitro identification and characterization of CD133pos cancer stem-like cells in anaplastic thyroid carcinoma cell lines. PLoS One. 2008;3(10):e3544.
- 12. Schweppe RE, Klopper JP, Korch C et al. Deoxyribonucleic acid profiling analysis of 40 human thyroid cancer cell lines reveals cross-contamination resulting in cell line redundancy and misidentification. J Clin Endocrinol Metab. 2008;93(11):4331–41.
- 13. Todaro M, Iovino F, Eterno V et al. Tumorigenic and metastatic activity of human thyroid cancer stem cells. Cancer Res. 2010;70(21):8874–85.
- 14. Giordano TJ. The Cancer Genome Atlas Research Network: A Sight to Behold. Endocr Pathol [Internet]. 2014 Dec;25(4):362–5. Available from: https://doi.org/10.1007/s12022-014-9345-4
- 15. Lawrence: Mutational heterogeneity in cancer and... – Google Hayka [Internet]. [cited 2020 Jan 2]. Available from: https://scholar.google.com/scholar_lookup?title=Mutational heterogeneity in cancer and the search for new cancer-associated genes&author=MS. Lawrence&author=P. Stojanov&author=P. Polak&journal=Nature&volume=499&pages=214-218&publication_year=2013
- 16. Nikiforova MN, Nikiforov YE. Molecular genetics of thyroid cancer: implications for diagnosis, treatment and prognosis. Expert Rev Mol Diagn. 2007/12/20. 2008;8(1):83–95.
- 17. Ahn HY, Chung YJ, Kim BS et al. Clinical significance of the BRAF V600E mutation in multifocal papillary thyroid carcinoma in Korea. Ahn HY, Chung YJ, Kim BS, Kang KH, Seok JW, Kim HS, et al., editors. Surgery [Internet]. 2014;155(4):689–95. Available from: http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Citation&list_uids=24612623
- 18. Xing M, Westra WH, Tufano RP et al. BRAF mutation predicts a poorer clinical prognosis for papillary thyroid cancer. J Clin Endocrinol Metab. 2005;90(12):6373–9.
- 19. Xing M, Alzahrani AS, Carson KA et al. Association between BRAF V600E mutation and mortality in patients with papillary thyroid cancer. Jama. 2013/04/11. 2013;309(14):1493–501.
- 20. Xing M. BRAF mutation in thyroid cancer. Endocr Relat Cancer. 2005;12(2):245–62.
- 21. Kim TH, Park YJ, Lim JA et al. The association of the BRAF(V600E) mutation with prognostic factors and poor clinical outcome in papillary thyroid cancer: a meta-analysis. Cancer. 2011/09/02. 2012;118(7):1764–73.
- 22. Kim KH, Kang DW, Kim SH et al. Mutations of the BRAF gene in papillary thyroid carcinoma in a Korean population. Yonsei Med J. 2004;45:818–21.
- 23. Nikiforov YE, Nikiforova MN. Molecular genetics and diagnosis of thyroid cancer. Nat Rev Endocrinol. 2011/09/01. 2011;7(10):569–80.
- 24. Kouba E, Ford A, Brown CG et al. Detection of BRAF V600E Mutations With Next-Generation Sequencing in Infarcted Thyroid Carcinomas After Fine-Needle Aspiration. Am J Clin Pathol [Internet]. 2018 Jul 3 [cited 2020 Jan 5];150(2):177–85. Available from: https://academic.oup.com/ajcp/article/150/2/177/5032503
- 25. Yu FX, Hu MX, Zhao HX et al. Precise Detection of Gene Mutations in Fine-Needle Aspiration Specimens of the Papillary Thyroid Microcarcinoma Using Next-Generation Sequencing. Int J Endocrinol. 2019;2019.
- 26. Couto JP, Prazeres H, Castro P et al. How molecular pathology is changing and will change the therapeutics of patients with follicular cell-derived thyroid cancer. J Clin Pathol. 2009;62(5):414–21.
- 27. Garcia-Rostan G, Zhao H, Camp RL et al. Ras mutations are associated with aggressive tumor phenotypes and poor prognosis in thyroid cancer. J Clin Oncol. 2003;21(17):3226–35.
- 28. Lacroix L, Lazar V, Michiels S et al. Follicular thyroid tumors with the PAX8-PPARγ1 rearrangement display characteristic genetic alterations. Am J Pathol. 2005;167(1):223–31.
- 29. Nikiforova MN, Lynch RA, Biddinger PWet al. RAS point mutations and PAX8-PPARγ rearrangement in thyroid tumors: evidence for distinct molecular pathways in thyroid follicular carcinoma. J Clin Endocrinol Metab. 2003;88(5):2318–26.
- 30. Gandhi M, Evdokimova V, Nikiforov YE. Mechanisms of chromosomal rearrangements in solid tumors: the model of papillary thyroid carcinoma. Mol Cell Endocrinol. 2010;321(1):36–43.
- 31. Unger K, Zitzelsberger H, Salvatore G et al. Heterogeneity in the distribution of RET/PTC rearrangements within individual post-Chernobyl papillary thyroid carcinomas. J Clin Endocrinol Metab. 2004;89(9):4272–9.
- 32. Zhu Z, Ciampi R, Nikiforova MN et al. Prevalence of RET/PTC rearrangements in thyroid papillary carcinomas: effects of the detection methods and genetic heterogeneity. J Clin Endocrinol Metab. 2006;91(9):3603–10.
- 33. Ciampi R, Nikiforov YE. RET/PTC rearrangements and BRAF mutations in thyroid tumorigenesis. Endocrinology. 2007;148(3):936–41.
- 34. Knauf JA, Kuroda H, Basu S, Fagin JA. RET/PTC-induced dedifferentiation of thyroid cells is mediated through Y1062 signaling through SHC-RAS-MAP kinase. Oncogene. 2003;22(28):4406.
- 35. Witt RL, Ferris RL, Pribitkin EA et al. Diagnosis and management of differentiated thyroid cancer using molecular biology. Laryngoscope. 2013;123(4):1059–64.
- 36. Xing M. Genetic alterations in the phosphatidylinositol-3 kinase/Akt pathway in thyroid cancer. Thyroid. 2010;20(7):697–706.
- 37. Nikiforova MN, Wald AI, Roy S et al. Targeted next-generation sequencing panel (ThyroSeq) for detection of mutations in thyroid cancer. J Clin Endocrinol Metab. 2013;98(11):E1852–60.
- 38. Garcia-Rostan G, Camp RL, Herrero A et al. β-catenin dys-regulation in thyroid neoplasms: down-regulation, aberrant nuclear expression, and CTNNB1 exon 3 mutations are markers for aggressive tumor phenotypes and poor prognosis. Am J Pathol. 2001;158(3):987–96.
- 39. Salajegheh A, Vosgha H, Rahman MA et al. Interactive role of miR-126 on VEGF-A and progression of papillary and undifferentiated thyroid carcinoma. Hum Pathol. 2016 May 1;51:75–85.
- 40. Yoruker EE, Terzioglu D, Teksoz S et al. MicroRNA expression profiles in papillary thyroid carcinoma, benign thyroid nodules and healthy controls. J Cancer. 2016;7(7):803–9.
- 41. Lee JC, Zhao JT, Clifton-Bligh RJ et al. MicroRNA-222 and MicroRNA-146b are tissue and circulating biomarkers of recurrent papillary thyroid cancer. Cancer. 2013 Dec 15;119(24):4358–65.
- 42. Xiang D, Tian B, Yang T, Li Z. miR-222 expression is correlated with the ATA risk stratifications in papillary thyroid carcinomas. Medicine (Baltimore). 2019 Jun 1;98(25):e16050.
- 43. Pallante P, Battista S, Pierantoni GM, Fusco A. Deregulation of microRNA expression in thyroid neoplasias. Pallante P, Battista S, Pierantoni GM, Fusco A, editors. Nat Rev Endocrinol [Internet]. 2013/11/20. 10(2):88–101. Available from: http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Citation&list_uids=24247220
- 44. He H, Jazdzewski K, Li W et al. The role of microRNA genes in papillary thyroid carcinoma. Proc Natl Acad Sci U S A. 2005 Dec 27;102(52):19075–80.
- 45. Zhang J, Wang J, Zhao F et al MicroRNA-21 (miR-21) represses tumor suppressor PTEN and promotes growth and invasion in non-small cell lung cancer (NSCLC). Clin Chim Acta [Internet]. 2010 Jun 3 [cited 2020 Jan 5];411(11–12):846–52. Available from: http://www.ncbi.nlm.nih.gov/pubmed/20223231
- 46. Hu J, Li C, Liu C et al. Expressions of miRNAs in papillary thyroid carcinoma and their associations with the clinical characteristics of PTC. Cancer Biomark [Internet]. 2017 [cited 2020 Jan 5];18(1):87–94. Available from: http://www.ncbi.nlm.nih.gov/pubmed/28085013
- 47. Swierniak M, Pfeifer A, Stokowy T et al. Somatic mutation profiling of follicular thyroid cancer by next generation sequencing. Mol Cell Endocrinol [Internet]. 2016 Sep 15 [cited 2020 Jan 2];433:130–7. Available from: https://www.sciencedirect.com/science/article/pii/S0303720716302076
- 48. Lu Z, Zhang Y, Feng D et al. Targeted next generation sequencing identifies somatic mutations and gene fusions in papillary thyroid carcinoma. Oncotarget. 2017;8(28):45784–92.
- 49. Nikiforov YE, Steward DL, Carty SE et al. Performance of a Multigene Genomic Classifier in Thyroid Nodules with Indeterminate Cytology: A Prospective Blinded Multicenter Study. JAMA Oncol. 2019 Feb 1;5(2):204–12.
- 50. Nikiforov YE, Baloch ZW. Clinical validation of the ThyroSeq v3 genomic classifier in thyroid nodules with indeterminate FNA cytology. Vol. 127, Cancer Cytopathology. John Wiley and Sons Inc.; 2019. p. 225–30.
- 51. Nicholson KJ, Roberts MS, McCoy KL et al. Molecular Testing Versus Diagnostic Lobectomy in Bethesda III/IV Thyroid Nodules: A Cost-Effectiveness Analysis. Thyroid. 2019 Sep 1;29(9):1237–43.